Compare McKesson Corporation (MCK) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ZIM Integrated Shipping Services Ltd — how do they compare? McKesson Corporation trades at $884.59 (market cap $105.14B), while ZIM Integrated Shipping Services Ltd trades at $25.31 (market cap $2.96B). The key difference: McKesson Corporation is far larger — about 35.5× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| MCK | ZIM | |
|---|---|---|
Market Cap | $105.14B | $2.96B |
Sector | Health | Industrials |
52-Week High | $995.69 | $29.27 |
52-Week Low | $659.01 | $12.44 |
Enterprise Value | $111.67B | $6.81B |
Dividend Yield | 0.42% | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
ZIM trades at $25.29, up 0.32% on the day, amid a bearish technical outlook and mixed earnings performance. The stock shows weak profitability with a net margin of 1.56% and declining revenue projections for 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and upcoming Q2 2026 earnings, with analyst sentiment evenly split between hold and sell recommendations.
The outlook for ZIM is cautious, with risks from merger uncertainty and operational pressures outweighing its low valuation multiples. Investment opportunity hinges on successful execution and merger approval, but current fundamentals and bearish technicals suggest limited near-term upside amid high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
